Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines | PLOS ONE
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy | Leukemia
![PDF] Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9fafead40352c90508f95afefb569266941b8712/6-Figure4-1.png "PDF] Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar")
PDF] Advances toward LSD1 inhibitors for cancer therapy. | Semantic Scholar
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia | Leukemia
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function | PNAS
Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 | Journal of Medicinal Chemistry
Molecules | Free Full-Text | Pharmacological Inhibition of LSD1 for Cancer Treatment | HTML
Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acid–induced differentiation | Science Advances
Medicinal chemistry insights in the discovery of novel LSD1 inhibitors | Epigenomics
Summary of LSD1/KDM1A inhibitors in clinical trials and clinical use. a | Download Table
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation - ScienceDirect
Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1) | Journal of Medicinal Chemistry
LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor
LSD1 inhibitors in clinical trials. (A) Structure of TCP-based... | Download Scientific Diagram
Cancers | Free Full-Text | LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target | HTML
Irreversible TCP-based LSD1 inhibitors 19-24. | Download Scientific Diagram
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
Frontiers | LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells
LSD1/KDM1A inhibitors in clinical trials: advances and prospects | Journal of Hematology & Oncology | Full Text
LSD1 inhibition induces differentiation and cell death in Merkel cell carcinoma | EMBO Molecular Medicine
Advances toward LSD1 inhibitors for cancer therapy | Future Medicinal Chemistry
Frontiers | A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED)
